{"id":20797,"date":"2020-06-05T14:08:00","date_gmt":"2020-06-05T14:08:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2584231"},"modified":"2020-06-05T14:08:00","modified_gmt":"2020-06-05T14:08:00","slug":"covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/","title":{"rendered":"COVID vaccine execs hyped vague data to cash in $90M in stock, watchdog says"},"content":{"rendered":"<h2>Executives allegedly &ldquo;exploited widespread fears&rdquo; of pandemic to make millions.<\/h2>\n<section class=\"post-meta\">\n<p>An anti-corruption watchdog is pressing the US Securities and Exchange Commission to investigate executives of the biotech company Moderna after they cashed in about $90 million in company shares days after promoting &ldquo;positive&#8221; but vague data from its early COVID-19 vaccine clinical trial.<\/p>\n<p>The watchdog group, Accountable.US, called the timing of the trades suspicious and questioned whether executives coordinated their stock sales prior to the data release.<\/p>\n<p>In a letter to the SEC that was&nbsp;<a href=\"https:\/\/www.cbsnews.com\/news\/insider-trading-allegations-moderna-accountable-us-securities-exchange-commission\/\">released to CBS Moneywatch<\/a>, Accountable.US President Kyle Herrig wrote, &#8220;This misconduct was particularly egregious because it involved not only financial fraud and manipulation of the financial markets, but also because it exploited widespread fears surrounding the ongoing COVID-19 pandemic.&rdquo; In all, the executives&#8217; exploitation served to &#8220;boost the company&#8217;s value, as well as their own bank accounts.<\/p>\n<p>&ldquo;I strongly urge the SEC to investigate these matters,&#8221; Herrig wrote.<\/p>\n<p>Moderna is considered a front-runner in the race for a vaccine against the pandemic virus, SARS-CoV-2. The company is testing a vaccine involving mRNA,&nbsp;<a href=\"https:\/\/arstechnica.com\/science\/2020\/05\/the-ars-covid-19-vaccine-primer-100-plus-in-the-works-8-in-clinical-trials\/\">an unproven vaccine platform<\/a>&nbsp;that is not used for any existing vaccines. However, Moderna became prominent in the pandemic after&nbsp;<a href=\"https:\/\/www.nih.gov\/news-events\/news-releases\/nih-clinical-trial-investigational-vaccine-covid-19-begins\">partnering with the National Institutes of Health<\/a>&nbsp;to design and test its vaccine. It was the very first vaccine to go into clinical trials, which began March 16.<\/p>\n<p>On May 18, the company sent out&nbsp;<a href=\"https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine\">a press release<\/a>&nbsp;saying that eight trial participants had developed neutralizing antibodies at levels that mimicked those seen in people who recover from a SARS-CoV-2 infection. Moderna painted the results as &ldquo;positive,&rdquo; but&nbsp;<a href=\"https:\/\/www.healthnewsreview.org\/2020\/05\/warning-early-vaccine-trial-results-dont-always-stand-test-of-time\/\">experts were quick to note<\/a>&nbsp;that the press release didn&rsquo;t contain any data and that the scant information provided is&nbsp;<a href=\"https:\/\/www.washingtonpost.com\/opinions\/2020\/05\/19\/rush-share-good-news-covid-19-drugs-is-undermining-science\/\">uninterpretable in terms of assessing the efficacy of the vaccine<\/a>. Some also questioned why Moderna chose to release such incomplete data from a very small number of participants instead of waiting to publish a larger dataset in a peer-reviewed scientific journal&mdash;which is standard practice.<\/p>\n<p>Still, the press release set off&nbsp;<a href=\"https:\/\/www.statnews.com\/2020\/05\/18\/early-data-show-moderna-covid-19-vaccine-generates-immune-response\/\">a frenzy of &#8220;encouraging&#8221; coverage<\/a>, and Moderna&rsquo;s stock surged 30 percent, raising it to an all-time high of $87 a share. Amid the surge, Moderna&rsquo;s CEO, several executives, and funds controlled by the chairman of the board sold about $90 million worth of stock, according to CBS Moneywatch.<\/p>\n<p>Though the company&rsquo;s shares eventually sank and are now at $59 a share, CBS notes that executives are still cashing in millions of dollars&rsquo; worth of stock.<\/p>\n<p>In a statement, Moderna defended the moves, saying, &ldquo;Executive sales are made under pre-planned 10b5-1 plans, which are executed during open trading windows in accordance with the company&#8217;s insider trading policy.&#8221; The company said it does not comment on potential investigations.<\/p>\n<\/section>\n<p class=\"tags\">\n<div><strong>See Campaign: <\/strong><a href=\"https:\/\/www.cbsnews.com\/news\/insider-trading-allegations-moderna-accountable-us-securities-exchange-commission\/\" target=\"_blank\">https:\/\/www.cbsnews.com\/news\/insider-trading-allegations-moderna-accountable-us-securities-exchange-commission\/<\/a><br \/><b>Contact Information:<\/b><br \/>BETH MOLE at  beth.mole@arstechnica.com<\/p>\n<p><b>Tags:<\/b><br \/><a href=\"\"><\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/wire\/\" rel=\"category tag\">Wire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/global-regions\/united-states\/\" rel=\"category tag\">United States<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/language\/english\/\" rel=\"category tag\">English<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"\" alt=\"image\" width=\"400\" height=\"300\" class=\"cwdfimg\" \/><\/div>\n<div>\n<h3>Contact Information:<\/h3>\n<p>BETH MOLE at  beth.mole@arstechnica.com<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Executives allegedly &ldquo;exploited widespread fears&rdquo; of pandemic to make millions. An anti-corruption watchdog is pressing the US Securities and Exchange Commission to investigate executives of the biotech company Moderna after they cashed in about $90 million in company shares days after promoting &ldquo;positive&rdquo; but vague data from its early COVID-19 vaccine clinical trial. The watchdog &hellip; <a href=\"https:\/\/icrowdnewswire.com\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/\">Continue reading <span>COVID vaccine execs hyped vague data to cash in $90M in stock, watchdog says<\/span><\/a> <a href=\"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":107,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,22,54],"tags":[],"class_list":["post-20797","post","type-post","status-publish","format-standard","hentry","category-english","category-united-states","category-wire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>COVID vaccine execs hyped vague data to cash in $90M in stock, watchdog says - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"COVID vaccine execs hyped vague data to cash in $90M in stock, watchdog says - Business\" \/>\n<meta property=\"og:description\" content=\"Executives allegedly &ldquo;exploited widespread fears&rdquo; of pandemic to make millions. An anti-corruption watchdog is pressing the US Securities and Exchange Commission to investigate executives of the biotech company Moderna after they cashed in about $90 million in company shares days after promoting &ldquo;positive&rdquo; but vague data from its early COVID-19 vaccine clinical trial. The watchdog &hellip; Continue reading COVID vaccine execs hyped vague data to cash in $90M in stock, watchdog says Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-05T14:08:00+00:00\" \/>\n<meta name=\"author\" content=\"Sarim Pixako\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sarim Pixako\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/\",\"url\":\"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/\",\"name\":\"COVID vaccine execs hyped vague data to cash in $90M in stock, watchdog says - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"datePublished\":\"2020-06-05T14:08:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/c2a30f1f67fb81890ad62e1daf092377\"},\"breadcrumb\":{\"@id\":\"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"COVID vaccine execs hyped vague data to cash in $90M in stock, watchdog says\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/c2a30f1f67fb81890ad62e1daf092377\",\"name\":\"Sarim Pixako\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7f9acce50c9b44bcec82e92168491959d754000e22e22a437856e37c38599249?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7f9acce50c9b44bcec82e92168491959d754000e22e22a437856e37c38599249?s=96&d=mm&r=g\",\"caption\":\"Sarim Pixako\"},\"sameAs\":[\"https:\/\/icrowdnewswire.com\/fc\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/sarim-pixako\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"COVID vaccine execs hyped vague data to cash in $90M in stock, watchdog says - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/","og_locale":"en_US","og_type":"article","og_title":"COVID vaccine execs hyped vague data to cash in $90M in stock, watchdog says - Business","og_description":"Executives allegedly &ldquo;exploited widespread fears&rdquo; of pandemic to make millions. An anti-corruption watchdog is pressing the US Securities and Exchange Commission to investigate executives of the biotech company Moderna after they cashed in about $90 million in company shares days after promoting &ldquo;positive&rdquo; but vague data from its early COVID-19 vaccine clinical trial. The watchdog &hellip; Continue reading COVID vaccine execs hyped vague data to cash in $90M in stock, watchdog says Continue Reading &rarr;","og_url":"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/","og_site_name":"Business","article_published_time":"2020-06-05T14:08:00+00:00","author":"Sarim Pixako","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sarim Pixako","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/","url":"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/","name":"COVID vaccine execs hyped vague data to cash in $90M in stock, watchdog says - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"datePublished":"2020-06-05T14:08:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/c2a30f1f67fb81890ad62e1daf092377"},"breadcrumb":{"@id":"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ipsnews.net\/business\/2020\/06\/05\/covid-vaccine-execs-hyped-vague-data-to-cash-in-90m-in-stock-watchdog-says-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"COVID vaccine execs hyped vague data to cash in $90M in stock, watchdog says"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/c2a30f1f67fb81890ad62e1daf092377","name":"Sarim Pixako","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7f9acce50c9b44bcec82e92168491959d754000e22e22a437856e37c38599249?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f9acce50c9b44bcec82e92168491959d754000e22e22a437856e37c38599249?s=96&d=mm&r=g","caption":"Sarim Pixako"},"sameAs":["https:\/\/icrowdnewswire.com\/fc"],"url":"https:\/\/ipsnews.net\/business\/author\/sarim-pixako\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/20797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/107"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=20797"}],"version-history":[{"count":1,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/20797\/revisions"}],"predecessor-version":[{"id":20798,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/20797\/revisions\/20798"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=20797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=20797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=20797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}